<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26168215</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1558-8238</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>125</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J Clin Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.</ArticleTitle>
        <Pagination>
          <StartPage>3356</StartPage>
          <EndPage>3364</EndPage>
          <MedlinePgn>3356-64</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI80005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">80005</ELocationID>
        <Abstract>
          <AbstractText>Our understanding of the role of myeloid-derived suppressor cells (MDSCs) in cancer is becoming increasingly complex. In addition to their eponymous role in suppressing immune responses, they directly support tumor growth, differentiation, and metastasis in a number of ways that are only now beginning to be appreciated. It is because of this increasingly complex role that these cells may become an important factor in the treatment of human cancer. In this Review, we discuss the most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression and highlight how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Marvel</LastName>
            <ForeName>Douglas</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gabrilovich</LastName>
            <ForeName>Dmitry I</ForeName>
            <Initials>DI</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA010815</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA 100062</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA141438</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA 141438</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA100062</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA009171</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>07</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007111" MajorTopicYN="Y">Immunity, Cellular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26168215</ArticleId>
        <ArticleId IdType="pmc">PMC4588239</ArticleId>
        <ArticleId IdType="doi">10.1172/JCI80005</ArticleId>
        <ArticleId IdType="pii">80005</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gabrilovich DI, et al.  The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67(1):425–426. doi: 10.1158/0008-5472.CAN-06-3037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3037</ArticleId>
            <ArticleId IdType="pmc">PMC1941787</ArticleId>
            <ArticleId IdType="pubmed">17210725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett JA, Rao VS, Mitchell MS. Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells. Proc Natl Acad Sci U S A. 1978;75(10):5142–5144. doi: 10.1073/pnas.75.10.5142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.75.10.5142</ArticleId>
            <ArticleId IdType="pmc">PMC336280</ArticleId>
            <ArticleId IdType="pubmed">283421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolcetti L, et al.  Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40(1):22–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19941314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–5802. doi: 10.4049/jimmunol.181.8.5791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.8.5791</ArticleId>
            <ArticleId IdType="pmc">PMC2575748</ArticleId>
            <ArticleId IdType="pubmed">18832739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movahedi K, et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233–4244. doi: 10.1182/blood-2007-07-099226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-07-099226</ArticleId>
            <ArticleId IdType="pubmed">18272812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13(10):739–752. doi: 10.1038/nrc3581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3581</ArticleId>
            <ArticleId IdType="pmc">PMC4358792</ArticleId>
            <ArticleId IdType="pubmed">24060865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damuzzo V, et al.  Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom. 2015;88(2):77–91. doi: 10.1002/cyto.b.21206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cyto.b.21206</ArticleId>
            <ArticleId IdType="pmc">PMC4405078</ArticleId>
            <ArticleId IdType="pubmed">25504825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridlender ZG, et al.  Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194. doi: 10.1016/j.ccr.2009.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.06.017</ArticleId>
            <ArticleId IdType="pmc">PMC2754404</ArticleId>
            <ArticleId IdType="pubmed">19732719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013;62(11):1745–1756. doi: 10.1007/s00262-013-1476-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-013-1476-9</ArticleId>
            <ArticleId IdType="pubmed">24092389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167–181. doi: 10.1189/jlb.0311177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0311177</ArticleId>
            <ArticleId IdType="pmc">PMC3250305</ArticleId>
            <ArticleId IdType="pubmed">21954284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756–4760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11406548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trellakis S, et al.  Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun. 2013;19(3):328–336. doi: 10.1177/1753425912463618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1753425912463618</ArticleId>
            <ArticleId IdType="pubmed">23160385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang B, et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–1131. doi: 10.1158/0008-5472.CAN-05-1299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-1299</ArticleId>
            <ArticleId IdType="pubmed">16424049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol. 2009;182(1):240–249. doi: 10.4049/jimmunol.182.1.240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.182.1.240</ArticleId>
            <ArticleId IdType="pubmed">19109155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkabets M, et al.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40(12):3347–3357. doi: 10.1002/eji.201041037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201041037</ArticleId>
            <ArticleId IdType="pmc">PMC3373225</ArticleId>
            <ArticleId IdType="pubmed">21110318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2011;46(2):156–164. doi: 10.3109/00365521.2010.516450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00365521.2010.516450</ArticleId>
            <ArticleId IdType="pubmed">20822377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao Y, et al.  Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 2013;73(13):3877–3887. doi: 10.1158/0008-5472.CAN-12-4115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-4115</ArticleId>
            <ArticleId IdType="pubmed">23633486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, Nelson A, Youn JI, Cheng P, Quiceno D, Gabrilovich DI. Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012;72(4):928–938. doi: 10.1158/0008-5472.CAN-11-2863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-2863</ArticleId>
            <ArticleId IdType="pmc">PMC4062074</ArticleId>
            <ArticleId IdType="pubmed">22237629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita M, et al.  COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011;71(7):2664–2674. doi: 10.1158/0008-5472.CAN-10-3055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-3055</ArticleId>
            <ArticleId IdType="pmc">PMC3075086</ArticleId>
            <ArticleId IdType="pubmed">21324923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68–77. doi: 10.1158/0008-5472.CAN-09-2587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-2587</ArticleId>
            <ArticleId IdType="pmc">PMC2805057</ArticleId>
            <ArticleId IdType="pubmed">20028852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol. 2009;183(2):937–944. doi: 10.4049/jimmunol.0804253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0804253</ArticleId>
            <ArticleId IdType="pmc">PMC2800824</ArticleId>
            <ArticleId IdType="pubmed">19553533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105–115. doi: 10.1111/imm.12036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imm.12036</ArticleId>
            <ArticleId IdType="pmc">PMC3575763</ArticleId>
            <ArticleId IdType="pubmed">23216602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268. doi: 10.1038/nri3175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3175</ArticleId>
            <ArticleId IdType="pmc">PMC3587148</ArticleId>
            <ArticleId IdType="pubmed">22437938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828–835. doi: 10.1038/nm1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1609</ArticleId>
            <ArticleId IdType="pmc">PMC2135607</ArticleId>
            <ArticleId IdType="pubmed">17603493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu T, et al.  Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. 2011;121(10):4015–4029. doi: 10.1172/JCI45862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI45862</ArticleId>
            <ArticleId IdType="pmc">PMC3195459</ArticleId>
            <ArticleId IdType="pubmed">21911941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molon B, et al.  Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208(10):1949–1962. doi: 10.1084/jem.20101956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20101956</ArticleId>
            <ArticleId IdType="pmc">PMC3182051</ArticleId>
            <ArticleId IdType="pubmed">21930770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haverkamp JM, et al.  Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014;41(6):947–959. doi: 10.1016/j.immuni.2014.10.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.020</ArticleId>
            <ArticleId IdType="pmc">PMC4272664</ArticleId>
            <ArticleId IdType="pubmed">25500368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava MK, et al.  Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 2012;7(7):e40677. doi: 10.1371/journal.pone.0040677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0040677</ArticleId>
            <ArticleId IdType="pmc">PMC3398024</ArticleId>
            <ArticleId IdType="pubmed">22815789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsukamoto H, Nishikata R, Senju S, Nishimura Y. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res. 2013;1(1):64–76. doi: 10.1158/2326-6066.CIR-13-0030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0030</ArticleId>
            <ArticleId IdType="pubmed">24777249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer MA, et al.  CD11b+, Ly6G+ cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection. PLoS Pathog. 2011;7(11):e1002374. doi: 10.1371/journal.ppat.1002374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1002374</ArticleId>
            <ArticleId IdType="pmc">PMC3213107</ArticleId>
            <ArticleId IdType="pubmed">22102816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mauti LA, et al.  Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J Clin Invest. 2011;121(7):2794–2807. doi: 10.1172/JCI41936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI41936</ArticleId>
            <ArticleId IdType="pmc">PMC3223816</ArticleId>
            <ArticleId IdType="pubmed">21646719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, et al.  Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–3797. doi: 10.4049/jimmunol.1201449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1201449</ArticleId>
            <ArticleId IdType="pubmed">23440412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sevko A, Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer. 2013;4(1):3–11. doi: 10.7150/jca.5047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.5047</ArticleId>
            <ArticleId IdType="pmc">PMC3564242</ArticleId>
            <ArticleId IdType="pubmed">23386900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortiz M, Lu L, Ramachandran I, Gabrilovich D. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res. 2014;2(1):50–58. doi: 10.1158/2326-6066.CIR-13-0129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0129</ArticleId>
            <ArticleId IdType="pmc">PMC4007346</ArticleId>
            <ArticleId IdType="pubmed">24778162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tartour E, et al.  Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30(1):83–95. doi: 10.1007/s10555-011-9281-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-011-9281-4</ArticleId>
            <ArticleId IdType="pubmed">21249423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casella I, et al.  Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101(4):1316–1323. doi: 10.1182/blood-2002-07-2184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2002-07-2184</ArticleId>
            <ArticleId IdType="pubmed">12406876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106(16):6742–6747. doi: 10.1073/pnas.0902280106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0902280106</ArticleId>
            <ArticleId IdType="pmc">PMC2665197</ArticleId>
            <ArticleId IdType="pubmed">19346489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, et al.  TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094–4104. doi: 10.1172/JCI64115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI64115</ArticleId>
            <ArticleId IdType="pmc">PMC3484453</ArticleId>
            <ArticleId IdType="pubmed">23064360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev. 2006;25(4):521–529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17186383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith HA, Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med. 2013;91(4):411–429. doi: 10.1007/s00109-013-1021-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00109-013-1021-5</ArticleId>
            <ArticleId IdType="pmc">PMC3697909</ArticleId>
            <ArticleId IdType="pubmed">23515621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan HH, et al.  Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010;70(15):6139–6149. doi: 10.1158/0008-5472.CAN-10-0706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-0706</ArticleId>
            <ArticleId IdType="pmc">PMC4675145</ArticleId>
            <ArticleId IdType="pubmed">20631080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8(12):1369–1375. doi: 10.1038/ncb1507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1507</ArticleId>
            <ArticleId IdType="pubmed">17128264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erler JT, et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35–44. doi: 10.1016/j.ccr.2008.11.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.11.012</ArticleId>
            <ArticleId IdType="pmc">PMC3050620</ArticleId>
            <ArticleId IdType="pubmed">19111879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng J, et al.  S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012;21(5):642–654. doi: 10.1016/j.ccr.2012.03.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.03.039</ArticleId>
            <ArticleId IdType="pmc">PMC3360884</ArticleId>
            <ArticleId IdType="pubmed">22624714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui TX, et al.  Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611–621. doi: 10.1016/j.immuni.2013.08.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.08.025</ArticleId>
            <ArticleId IdType="pmc">PMC3831370</ArticleId>
            <ArticleId IdType="pubmed">24012420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toh B, et al.  Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9):e1001162. doi: 10.1371/journal.pbio.1001162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.1001162</ArticleId>
            <ArticleId IdType="pmc">PMC3181226</ArticleId>
            <ArticleId IdType="pubmed">21980263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh K, et al.  A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):R79. doi: 10.1186/bcr3473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr3473</ArticleId>
            <ArticleId IdType="pmc">PMC3979084</ArticleId>
            <ArticleId IdType="pubmed">24021059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>To Y, et al.  A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol. 2002;27(2):220–226. doi: 10.1165/ajrcmb.27.2.4804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/ajrcmb.27.2.4804</ArticleId>
            <ArticleId IdType="pubmed">12151314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colomiere M, et al.  Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 2009;100(1):134–144. doi: 10.1038/sj.bjc.6604794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604794</ArticleId>
            <ArticleId IdType="pmc">PMC2634691</ArticleId>
            <ArticleId IdType="pubmed">19088723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eruslanov EB, et al.  Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124(12):5466–5480. doi: 10.1172/JCI77053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI77053</ArticleId>
            <ArticleId IdType="pmc">PMC4348966</ArticleId>
            <ArticleId IdType="pubmed">25384214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortiz ML, et al.  Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells. J Exp Med. 2015;212(3):351–367. doi: 10.1084/jem.20140835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20140835</ArticleId>
            <ArticleId IdType="pmc">PMC4354367</ArticleId>
            <ArticleId IdType="pubmed">25667306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Mitri D, et al.  Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 2014;515(7525):134–137. doi: 10.1038/nature13638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13638</ArticleId>
            <ArticleId IdType="pubmed">25156255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19–25. doi: 10.1016/j.it.2010.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2010.10.002</ArticleId>
            <ArticleId IdType="pmc">PMC3053028</ArticleId>
            <ArticleId IdType="pubmed">21067974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayne LJ, et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21(6):822–835. doi: 10.1016/j.ccr.2012.04.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.04.025</ArticleId>
            <ArticleId IdType="pmc">PMC3575028</ArticleId>
            <ArticleId IdType="pubmed">22698406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marigo I, et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity. 2010;32(6):790–802. doi: 10.1016/j.immuni.2010.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2010.05.010</ArticleId>
            <ArticleId IdType="pubmed">20605485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. doi: 10.1038/nri2506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2506</ArticleId>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005;65(24):11743–11751. doi: 10.1158/0008-5472.CAN-05-0045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-0045</ArticleId>
            <ArticleId IdType="pubmed">16357187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, et al.  IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170(1):270–278. doi: 10.4049/jimmunol.170.1.270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.170.1.270</ArticleId>
            <ArticleId IdType="pubmed">12496409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko JS, et al.  Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70(9):3526–3536. doi: 10.1158/0008-5472.CAN-09-3278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3278</ArticleId>
            <ArticleId IdType="pmc">PMC3426924</ArticleId>
            <ArticleId IdType="pubmed">20406969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasquez-Dunddel D, et al.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580–1589. doi: 10.1172/JCI60083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI60083</ArticleId>
            <ArticleId IdType="pmc">PMC3613901</ArticleId>
            <ArticleId IdType="pubmed">23454751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart TJ, et al.  Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. J Cell Mol Med. 2009;13(9B):3939–3950. doi: 10.1111/j.1582-4934.2009.00685.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1582-4934.2009.00685.x</ArticleId>
            <ArticleId IdType="pmc">PMC3858838</ArticleId>
            <ArticleId IdType="pubmed">20196788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waight JD, et al.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest. 2013;123(10):4464–4478. doi: 10.1172/JCI68189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI68189</ArticleId>
            <ArticleId IdType="pmc">PMC3784535</ArticleId>
            <ArticleId IdType="pubmed">24091328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farren MR, et al.  Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance. Sci Signal. 2014;7(313):ra16. doi: 10.1126/scisignal.2004656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2004656</ArticleId>
            <ArticleId IdType="pmc">PMC4033697</ArticleId>
            <ArticleId IdType="pubmed">24550541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corzo CA, et al.  HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439–2453. doi: 10.1084/jem.20100587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20100587</ArticleId>
            <ArticleId IdType="pmc">PMC2964584</ArticleId>
            <ArticleId IdType="pubmed">20876310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noman MZ, et al.  PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–790. doi: 10.1084/jem.20131916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20131916</ArticleId>
            <ArticleId IdType="pmc">PMC4010891</ArticleId>
            <ArticleId IdType="pubmed">24778419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Zhou J, Cheng P, Ramachandran I, Nefedova Y, Gabrilovich DI. Regulation of dendritic cell differentiation in bone marrow during emergency myelopoiesis. J Immunol. 2013;191(4):1916–1926. doi: 10.4049/jimmunol.1300714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1300714</ArticleId>
            <ArticleId IdType="pmc">PMC3787311</ArticleId>
            <ArticleId IdType="pubmed">23833236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capietto AH, et al.  Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J Exp Med. 2013;210(11):2257–2271. doi: 10.1084/jem.20130281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20130281</ArticleId>
            <ArticleId IdType="pmc">PMC3804931</ArticleId>
            <ArticleId IdType="pubmed">24127488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer. Oncotarget. 2014;5(22):11345–11353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4294358</ArticleId>
            <ArticleId IdType="pubmed">25294811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahadevan NR, Anufreichik V, Rodvold JJ, Chiu KT, Sepulveda H, Zanetti M. Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8+ T cell priming. PLoS One. 2012;7(12):e51845. doi: 10.1371/journal.pone.0051845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0051845</ArticleId>
            <ArticleId IdType="pmc">PMC3525659</ArticleId>
            <ArticleId IdType="pubmed">23272178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahadevan NR, Rodvold J, Sepulveda H, Rossi S, Drew AF, Zanetti M. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proc Natl Acad Sci U S A. 2011;108(16):6561–6566. doi: 10.1073/pnas.1008942108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1008942108</ArticleId>
            <ArticleId IdType="pmc">PMC3081038</ArticleId>
            <ArticleId IdType="pubmed">21464300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, et al.  ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis. J Clin Invest. 2014;124(6):2626–2639. doi: 10.1172/JCI74056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI74056</ArticleId>
            <ArticleId IdType="pmc">PMC4038578</ArticleId>
            <ArticleId IdType="pubmed">24789911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081–1086. doi: 10.1126/science.1209038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1209038</ArticleId>
            <ArticleId IdType="pubmed">22116877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claudio N, Dalet A, Gatti E, Pierre P. Mapping the crossroads of immune activation and cellular stress response pathways. EMBO J. 2013;32(9):1214–1224. doi: 10.1038/emboj.2013.80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2013.80</ArticleId>
            <ArticleId IdType="pmc">PMC3642686</ArticleId>
            <ArticleId IdType="pubmed">23584529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thevenot PT, et al.  The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity. 2014;41(3):389–401. doi: 10.1016/j.immuni.2014.08.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.08.015</ArticleId>
            <ArticleId IdType="pmc">PMC4171711</ArticleId>
            <ArticleId IdType="pubmed">25238096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Gabrilovich DI. Can the suppressive activity of myeloid-derived suppressor cells be “chop”ped? Immunity. 2014;41(3):341–342. doi: 10.1016/j.immuni.2014.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.08.016</ArticleId>
            <ArticleId IdType="pubmed">25238087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee BR, et al.  Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells. Oncotarget. 2014;5(23):12331–12345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4322987</ArticleId>
            <ArticleId IdType="pubmed">25514597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker KH, et al.  HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014;74(20):5723–5733. doi: 10.1158/0008-5472.CAN-13-2347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-2347</ArticleId>
            <ArticleId IdType="pmc">PMC4199911</ArticleId>
            <ArticleId IdType="pubmed">25164013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu L, et al.  Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood. 2012;119(1):115–126. doi: 10.1182/blood-2011-06-363093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-06-363093</ArticleId>
            <ArticleId IdType="pmc">PMC3251224</ArticleId>
            <ArticleId IdType="pubmed">22053106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narita Y, Wakita D, Ohkur T, Chamoto K, Nishimura T. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed Res. 2009;30(1):7–15. doi: 10.2220/biomedres.30.7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2220/biomedres.30.7</ArticleId>
            <ArticleId IdType="pubmed">19265258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6(4):409–421. doi: 10.1016/j.ccr.2004.08.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2004.08.031</ArticleId>
            <ArticleId IdType="pubmed">15488763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65(20):9525–9535. doi: 10.1158/0008-5472.CAN-05-0529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-0529</ArticleId>
            <ArticleId IdType="pmc">PMC1351362</ArticleId>
            <ArticleId IdType="pubmed">16230418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong H, et al.  Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer. 2014;134(11):2633–2645. doi: 10.1002/ijc.28590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.28590</ArticleId>
            <ArticleId IdType="pmc">PMC4030414</ArticleId>
            <ArticleId IdType="pubmed">24443321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawant A, et al.  Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 2013;73(2):672–682. doi: 10.1158/0008-5472.CAN-12-2202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-2202</ArticleId>
            <ArticleId IdType="pmc">PMC3548966</ArticleId>
            <ArticleId IdType="pubmed">23243021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y, et al.  Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. Oncogenesis. 2014;24(3):44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4259966</ArticleId>
            <ArticleId IdType="pubmed">25417726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niedermeier M, et al.  CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci U S A. 2009;106(42):17892–17897. doi: 10.1073/pnas.0906070106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0906070106</ArticleId>
            <ArticleId IdType="pmc">PMC2764893</ArticleId>
            <ArticleId IdType="pubmed">19815530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoso A, et al.  Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol. 2014;44(11):3307–3319. doi: 10.1002/eji.201444522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201444522</ArticleId>
            <ArticleId IdType="pubmed">25113564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, et al.  Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 2013;122(7):1105–1113. doi: 10.1182/blood-2012-08-449413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2012-08-449413</ArticleId>
            <ArticleId IdType="pmc">PMC3744987</ArticleId>
            <ArticleId IdType="pubmed">23757729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, et al.  Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013;14(3):211–220. doi: 10.1038/ni.2526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2526</ArticleId>
            <ArticleId IdType="pmc">PMC3578019</ArticleId>
            <ArticleId IdType="pubmed">23354483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics. 2011;10(3):M110.002980. doi: 10.1074/mcp.M110.002980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M110.002980</ArticleId>
            <ArticleId IdType="pmc">PMC3047151</ArticleId>
            <ArticleId IdType="pubmed">21191032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, et al.  Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. J Biol Chem. 2013;288(26):19103–19115. doi: 10.1074/jbc.M112.434530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.434530</ArticleId>
            <ArticleId IdType="pmc">PMC3696683</ArticleId>
            <ArticleId IdType="pubmed">23677993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messmer MN, Netherby CS, Banik D, Abrams SI. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother. 2015;64(1):1–13. doi: 10.1007/s00262-014-1639-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-014-1639-3</ArticleId>
            <ArticleId IdType="pmc">PMC4282948</ArticleId>
            <ArticleId IdType="pubmed">25432147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319(1):47–65. doi: 10.1111/nyas.12469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.12469</ArticleId>
            <ArticleId IdType="pubmed">24965257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11(7):856–861. doi: 10.1016/j.intimp.2011.01.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2011.01.030</ArticleId>
            <ArticleId IdType="pmc">PMC3109226</ArticleId>
            <ArticleId IdType="pubmed">21315783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng PH, et al.  CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med. 2012;186(10):1025–1036. doi: 10.1164/rccm.201204-0636OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201204-0636OC</ArticleId>
            <ArticleId IdType="pmc">PMC4132576</ArticleId>
            <ArticleId IdType="pubmed">22955317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetsika E-K, et al.  A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res. 2014;2014:659294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4243712</ArticleId>
            <ArticleId IdType="pubmed">25436215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu CY, et al.  Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(–)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35–45. doi: 10.1007/s00432-009-0634-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-009-0634-0</ArticleId>
            <ArticleId IdType="pubmed">19572148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59. doi: 10.1007/s00262-008-0523-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-008-0523-4</ArticleId>
            <ArticleId IdType="pmc">PMC3401888</ArticleId>
            <ArticleId IdType="pubmed">18446337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sevko A, et al.  Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol. 2013;133(6):1610–1619. doi: 10.1038/jid.2012.444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2012.444</ArticleId>
            <ArticleId IdType="pubmed">23223128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segre M, Tomei E, Segre D. Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells. Cell Immunol. 1985;91(2):443–454. doi: 10.1016/0008-8749(85)90242-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0008-8749(85)90242-4</ArticleId>
            <ArticleId IdType="pubmed">3158396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer C, et al.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–257. doi: 10.1007/s00262-013-1508-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-013-1508-5</ArticleId>
            <ArticleId IdType="pubmed">24357148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarhini AA, et al.  Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705. doi: 10.1371/journal.pone.0087705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0087705</ArticleId>
            <ArticleId IdType="pmc">PMC3912016</ArticleId>
            <ArticleId IdType="pubmed">24498358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, et al.  Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. J Immunother. 2014;37(1):43–50. doi: 10.1097/CJI.0000000000000005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0000000000000005</ArticleId>
            <ArticleId IdType="pubmed">24316555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finkelstein SE, et al.  Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010;33(8):817–827. doi: 10.1097/CJI.0b013e3181ecccad.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0b013e3181ecccad</ArticleId>
            <ArticleId IdType="pubmed">20842055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura T, et al.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res. 2013;6(1):18–26. doi: 10.1158/1940-6207.CAPR-12-0275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-12-0275</ArticleId>
            <ArticleId IdType="pmc">PMC3536916</ArticleId>
            <ArticleId IdType="pubmed">23248097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wesolowski R, Markowitz J, Carson W. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1(1):10. doi: 10.1186/2051-1426-1-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2051-1426-1-10</ArticleId>
            <ArticleId IdType="pmc">PMC4019895</ArticleId>
            <ArticleId IdType="pubmed">24829747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–6721. doi: 10.1158/1078-0432.CCR-05-0883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-05-0883</ArticleId>
            <ArticleId IdType="pubmed">16166452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9(7–8):900–909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19336265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. Br J Cancer. 2014;110(1):83–93. doi: 10.1038/bjc.2013.695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.695</ArticleId>
            <ArticleId IdType="pmc">PMC3887295</ArticleId>
            <ArticleId IdType="pubmed">24281006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naiditch H, Shurin MR, Shurin GV. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunol Res. 2011;50(2–3):276–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21717082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent J, et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–3061. doi: 10.1158/0008-5472.CAN-09-3690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3690</ArticleId>
            <ArticleId IdType="pubmed">20388795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ugel S, et al.  Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012;2(3):628–639. doi: 10.1016/j.celrep.2012.08.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2012.08.006</ArticleId>
            <ArticleId IdType="pubmed">22959433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin H, et al.  Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. 2014;20(6):676–681. doi: 10.1038/nm.3560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3560</ArticleId>
            <ArticleId IdType="pmc">PMC4048321</ArticleId>
            <ArticleId IdType="pubmed">24859530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, et al.  Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010;16(6):1812–1823. doi: 10.1158/1078-0432.CCR-09-3272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-3272</ArticleId>
            <ArticleId IdType="pmc">PMC2840181</ArticleId>
            <ArticleId IdType="pubmed">20215551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafini P, et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691–2702. doi: 10.1084/jem.20061104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20061104</ArticleId>
            <ArticleId IdType="pmc">PMC2118163</ArticleId>
            <ArticleId IdType="pubmed">17101732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Califano JA, et al.  Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(1):30–38. doi: 10.1158/1078-0432.CCR-14-1716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1716</ArticleId>
            <ArticleId IdType="pmc">PMC4329916</ArticleId>
            <ArticleId IdType="pubmed">25564570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weed DT, et al.  Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(1):39–48. doi: 10.1158/1078-0432.CCR-14-1711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1711</ArticleId>
            <ArticleId IdType="pmc">PMC4322895</ArticleId>
            <ArticleId IdType="pubmed">25320361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez PC, et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931–939. doi: 10.1084/jem.20050715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050715</ArticleId>
            <ArticleId IdType="pmc">PMC2213169</ArticleId>
            <ArticleId IdType="pubmed">16186186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Santo C, et al.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A. 2005;102(11):4185–4190. doi: 10.1073/pnas.0409783102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0409783102</ArticleId>
            <ArticleId IdType="pmc">PMC554823</ArticleId>
            <ArticleId IdType="pubmed">15753302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63(15):4441–4449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12907617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, et al.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14(24):8270–8278. doi: 10.1158/1078-0432.CCR-08-0165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0165</ArticleId>
            <ArticleId IdType="pubmed">19088044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirza N, et al.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66(18):9299–9307. doi: 10.1158/0008-5472.CAN-06-1690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-1690</ArticleId>
            <ArticleId IdType="pmc">PMC1586106</ArticleId>
            <ArticleId IdType="pubmed">16982775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62(5):909–918. doi: 10.1007/s00262-013-1396-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-013-1396-8</ArticleId>
            <ArticleId IdType="pmc">PMC3662237</ArticleId>
            <ArticleId IdType="pubmed">23589106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012;30(9):1005–1014. doi: 10.1200/JCO.2010.31.8907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.31.8907</ArticleId>
            <ArticleId IdType="pmc">PMC3341105</ArticleId>
            <ArticleId IdType="pubmed">22355058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko JS, et al.  Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148–2157. doi: 10.1158/1078-0432.CCR-08-1332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-1332</ArticleId>
            <ArticleId IdType="pubmed">19276286</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
